News

Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides
SHELTON, CT / ACCESS Newswire / July 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of bro ...
Onlymyhealth on MSN6h
World’s First mRNA Vaccine Against Bubonic Plague: Israeli Scientists Make History
Israeli researchers create the world’s first 100 effective mRNA vaccine against Bubonic Plague paving the way for more ...